Cost-Effectiveness Analysis of Atezolizumab Versus Durvalumab as First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer in the USA

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

Leora Horn, Aaron S. Mansfield, Aleksandra Szczęsna et al. · New England Journal of Medicine · 2018 · 3.3K citations · Full text

Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold

Peter J. Neumann, Joshua T. Cohen, Milton C. Weinstein · New England Journal of Medicine · 2014 · 2.2K citations

Quality Of Life, Applied Economics, Primary Care +23

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet · 2019 · 2.1K citations

Platinum–etoposide Versus Platinum–etoposide, Medicine, Pharmacology +6

Health state utilities for non small cell lung cancer

Beenish Nafees, Megan Stafford, Sonia Gavriel et al. · Health and Quality of Life Outcomes · 2008 · 382 citations · Full text

United States Life Tables, 2018.

Elizabeth Arias, Jiaquan Xu · PubMed · 2020 · 373 citations

Family Medicine, Quality Of Life, Health Care Disparity +21